SCYL1BP1 has tumor-suppressive functions in human lung squamous carcinoma cells by regulating degradation of MDM2

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 17, 2014, Pages 7467-7471

  Yang, Zhi Ping ^a   Xie, Yong Hong ^b   Ling, Dan Yan ^c   Li, Jin Rui ^a   Jiang, Jin ^a   Fan, Yao Hua ^a   Zheng, Jia Lian ^a   Wu, Wan Xin ^a  

^a First Hospital of Jiaxing   (China)

^b JIAXING UNIVERSITY   (China)

^c Shanghai Fuchun Kexin Biotech Co Ltd   (China)

Author keywords

Lung squamous carcinoma cells; MDM2; SCYL1BP1; Suppressor action

Indexed keywords

CARRIER PROTEIN; MDM2 PROTEIN, HUMAN; PROTEIN MDM2; SCYL1BP1 PROTEIN, HUMAN;

ANIMAL; CANCER TRANSPLANTATION; CELL MOTION; CELL PROLIFERATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; MOUSE; NUDE MOUSE; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 84907270640     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.17.7467     Document Type: Article

References (34)

1. Bexiga MG, Simpson JC (2013). Human diseases associated with form and function of the Golgi complex. Int J Mol Sci, 14, 18670-81.
2. Brooks CL, Gu W (2006). p53 ubiquitination: Mdm2 and beyond. Mol Cell, 21, 307-15.
3. Chansaenroj J, Theamboonlers A, Junyangdikul P, et al (2013). Polymorphisms in TP53 (rs1042522), p16 (rs11515 and rs3088440) and NQO1 (rs1800566) genes in Thai cervical cancer patients with HPV 16 infection. Asian Pac J Cancer Prev, 14, 341-6.
4. Cordon-Cardo C, Latres E, Drobnjak M, et al (1994). Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res, 54, 794-9.
5. Di Y, Li J, Fang J, et al (2003). Cloning and characterization of a novel gene which encodes a protein interacting with the mitosis-associated kinase-like protein NTKL. J Hum Genet, 48, 315-21.
6. Grossman SR, Perez M, Kung AL, et al (1998). p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell, 2, 405-15.
7. Hennies HC, Kornak U, Zhang H, et al (2008). Gerodermia osteodysplastica is caused by mutations in SCYL1BP1, a Rab-6 interacting golgin. Nat Genet, 40, 1410-2.
8. Hu L, Liu M, Chen L, et al (2012). SCYL1 binding protein 1 promotes the ubiquitin-dependent degradation of Pirh2 and has tumor-suppressive function in the development of hepatocellular carcinoma. Carcinogenesis, 33, 1581-8.
9. Huang H, Tindall DJ (2011). Regulation of FOXO protein stability via ubiquitination and proteasome degradation. Biochim Biophys Acta, 1813, 1961-4.
10. Hwang-Verslues WW, Chang PH, Wei PC, et al (2011). miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1. Oncogene, 30, 2463-74.
11. Jackson PK, Eldridge AG, Freed E, et al (2000). The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol, 10, 429-39.
12. Kang DS, Tian X, Benovic JL (2014). Role of beta-arrestins and arrestin domain-containing proteins in G protein-coupled receptor trafficking. Curr Opin Cell Biol, 27, 63-71.
13. Legube G, Linares LK, Lemercier C, et al (2002). Tip60 is targeted to proteasome-mediated degradation by Mdm2 and accumulates after UV irradiation. EMBO J, 21, 1704-12.
14. Li W, Zheng J, Deng J, et al (2014). Increased levels of the long intergenic non-protein coding RNA POU3F3 promote DNA methylation in esophageal squamous cell carcinoma cells. Gastroenterology, 146, 1714-26.
15. Liu J, Zheng Y, Lei D, et al (2011). MDM2 309T>G polymorphism and risk of squamous cell carcinomas of head and neck: a meta-analysis. Asian Pac J Cancer Prev, 12, 1899-903.
16. Liu Y, Chen Y, Lu X, et al (2012). SCYL1BP1 modulates neurite outgrowth and regeneration by regulating the Mdm2/p53 pathway. Mol Biol Cell, 23, 4506-14.
17. Ma HB, Huang T, Han F, et al (2012). Association between MDM2 promoter SNP309 T/G polymorphism and liver cancer risk-a meta-analysis. Asian Pac J Cancer Prev, 13, 2841-6.
18. Manfredi JJ (2010). The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev, 24, 1580-9.
19. Martinez J, Georgoff I, Levine AJ (1991). Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev, 5, 151-9.
20. Momand J, Zambetti GP, Olson DC, et al (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237-45.
21. Polyak K, Lee MH, Erdjument-Bromage H, et al (1994). Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78, 59-66.
22. Sczaniecka M, Gladstone K, Pettersson S, et al (2012). MDM2 protein-mediated ubiquitination of numb protein: identification of a second physiological substrate of MDM2 that employs a dual-site docking mechanism. J Biol Chem, 287, 14052-68.
23. Shenoy SK, McDonald PH, Kohout TA, et al (2001). Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science, 294, 1307-13.
24. Sparks A, Dayal S, Das J, et al (2013). The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a. Oncogene, [Epub ahead of print].
25. Uldrijan S, Pannekoek WJ, Vousden KH (2007). An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J, 26, 102-12.
26. van der Laan S, Tsanov N, Crozet C, et al (2013). High Dub3 expression in mouse ESCs couples the G1/S checkpoint to pluripotency. Mol Cell, 52, 366-79.
27. Wade M, Li YC, Wahl GM (2013). MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer, 13, 83-96.
28. Wang SP, Wang WL, Chang YL, et al (2009). p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol, 11, 694-704.
29. Yan J, Di Y, Shi H, et al (2010a). Overexpression of SCYL1-BP1 stabilizes functional p53 by suppressing MDM2-mediated ubiquitination. FEBS Lett, 584, 4319-24.
30. Yan J, Zhang D, Di Y, et al (2010b). A newly identified Pirh2 substrate SCYL1-BP1 can bind to MDM2 and accelerate MDM2 self-ubiquitination. FEBS Lett, 584, 3275-8.
31. Yogosawa S, Miyauchi Y, Honda R, et al (2003). Mammalian Numb is a target protein of Mdm2, ubiquitin ligase. Biochem Biophys Res Commun, 302, 869-72.
32. Zheng J, Deng J, Xiao M, et al (2013). A sequence polymorphism in miR-608 predicts recurrence after radiotherapy for nasopharyngeal carcinoma. Cancer Res, 73, 5151-62.
33. Zheng J, Jiang L, Zhang L, et al (2012). Functional genetic variations in the IL-23 receptor gene are associated with risk of breast, lung and nasopharyngeal cancer in Chinese populations. Carcinogenesis, 33, 2409-16.
34. Zhou J, Wang W (2011). Analysis of microRNA expression profiling identifies microRNA-503 regulates metastatic function in hepatocellular cancer cell. J Surg Oncol, 104, 278-83.